Per the terms of the agreement, Sobi is expected to pay upwards of $950 million upfront in cash to acquire Arthrosi.The deal ...

The collaboration agreement joins Relation’s AI-powered drug discovery platform and human data generation capabilities with ...

Lilly’s first Phase III results for retatrutide show unprecedented weight loss and marked reductions in osteoarthritis pain, ...

Pfizer announced it has entered into an exclusive global collaboration and license agreement with Chongqing Yao ...

Brent Saunders returned to Bausch + Lomb in 2023 to help address unmet needs in eye care, focusing on innovation and ...

OTR Therapeutics and Zealand Pharma collaborate to develop novel metabolic disease treatments, with a potential deal value of ...

PE: How are global regulatory agencies adjusting their policies for biosimilars? Woollett: The clear leaders in the space of ...

Fondazione Telethon announced that FDA has approved its Biologics License Application (BLA) for Waskyra (etuvetidigene ...

PE: How will recent regulatory developments at FDA impact feasibility assessments in clinical planning? Woollett: It’s ...

For Phase III trial planning, two suggestions may have merit. Include sizeable subpopulations that payers cannot easily ...

DTC prescription drug models are reshaping the pharma industry by altering pricing dynamics and enhancing patient access, ...

In today’s Pharmaceutical Executive Daily, new analysis outlines what it may truly cost to fix the biopharma ecosystem, the ...